VivoSim Labs (NASDAQ:VIVS) Issues Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) released its earnings results on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.02 million for the quarter. VivoSim Labs had a negative net margin of 10,567.17% and a negative return on equity of 277.62%.

VivoSim Labs Price Performance

VIVS traded down $0.02 during mid-day trading on Wednesday, hitting $0.33. The stock had a trading volume of 2,099,275 shares, compared to its average volume of 2,913,147. The stock’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $1.39. The firm has a market capitalization of $1.16 million, a price-to-earnings ratio of -0.06 and a beta of 1.47. VivoSim Labs has a 1-year low of $0.31 and a 1-year high of $5.30.

Institutional Investors Weigh In On VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 8.23% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.